Development of a hepatocyte-specific prostaglandin E1 polymeric prodrug and its potential for preventing carbon tetrachloride-induced fulminant hepatitis in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 3, 1999, Pages 1242-1249

  Akamatsu, Ken ^a   Yamasaki, Yasuomi ^a   Nishikawa, Makiya ^a   Takakura, Yoshinobu ^a   Hashida, Mitsuru ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON TETRACHLORIDE; HYDRAZIDE DERIVATIVE; INDIUM 111; POLYGLUTAMIC ACID DERIVATIVE; POLYMER; PRODRUG; PROSTAGLANDIN E1 DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG DEGRADATION; DRUG LIVER LEVEL; DRUG SYNTHESIS; HEPATITIS; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; LIVER PROTECTION; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ACUTE DISEASE; ANIMALS; CARBON TETRACHLORIDE; DINOPROSTONE; DRUG CARRIERS; HEPATITIS, TOXIC; LIVER; MALE; MICE; ORGAN SPECIFICITY; OXYTOCICS; POLYGLUTAMIC ACID; PRODRUGS; TISSUE DISTRIBUTION;

EID: 0032794161     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. 1 polymeric prodrug. Int J Pharm 155:65-74.
2. Arano Y, Mukai T, Uezono T, Wakisaka K, Motonari H, Akizawa H, Taoka Y and Yokoyama A (1994) A biological method to evaluate bifunctional chelating agents to label antibodies with metallic radionuclides. J Nucl Med 35:890-898.
3. 1 administration in cirrhotic rats. Gastroenterology 105:1483-1489.
4. Blomhoff R, Blomhoff HK, Tolleshaug H, Christensen TB and Berg T (1985) Uptake and degradation of bovine testes beta-galactosidase by parenchymal and non-parenchymal rat liver cells. Int J Biochem 17:1321-1328.
5. Buncel C, Chuaqui C and Wilson H (1980) Reactivity-selectivity correlations. 3. The effect at saturated carbon: Reactivity studies of methyl phenyl sulfates with nucleophiles. J Org Chem 45:3621-3626.
6. Coessens V, Schacht E and Domurado D (1996) Synthesis of polyglutamine and dextran conjugates of streptomycin with an acid-sensitive drug-carrier linkage. J Control Release 38:141-150.
7. Duncan JR and Welch MJ (1993) Intracellular metabolism of indium 111-labeled receptor targeted proteins. J Nucl Med 34:1728-1738.
8. Edwards MJ, Keller BJ, Kauffman FC and Thurman RG (1993) The involvement of Kupffer cells in carbon tetrachloride toxicity. Toxicol Appl Pharmacol 119:275-279.
9. Ferruti P, Tanzi MC and Vaccaroni F (1979) Polymeric hydrazides by reaction with polymeric benzotriazolides. J Polym Sci Polym Chem Ed 17:277-279.
10. Fujita T, Furitsu M, Nishikawa M, Takakura Y, Sezaki H and Hashida M (1992a) Therapeutic effects of superoxide dismutase derivatives modified with mono- or polysaccharides on hepatic injury induced by ischemia/reperfusion. Biochem Biophys Res Commun 189:191-196.
11. Fujita T, Nishikawa M, Tamaki C, Takakura Y, Hashida M and Sezaki H (1992b) Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono- and polysaccharide derivatives. J Pharmacol Exp Ther 263: 971-978.
12. Gonsho A, Irie K, Susaki H, Iwasawa H, Okuno S and Sugawara T (1994) Tissue-targeting ability of saccharide-poly(L-lysine) conjugates. Biol Pharm Bull 17:275-282.
13. 1 in mice: Prostaglandins and related factors. Biochim Biophys Acta 106:379-385.
14. Hashida M, Hirabayashi H, Nishikawa M and Takakura Y (1997) Targeted delivery of drugs and proteins to the liver via receptor-mediated endocytosis. J Control Release 46:129-137.
15. 1 on liver adenine nucleotides and cytoplasmic enzymes in a porcine model of normothermic hepatic ischemia. Hepatology 22:1554-1559.
16. Hirabayashi H, Nishikawa M, Takakura Y and Hashida M (1996) Development and pharmacokinetics of galactosylated poly-L-glutamic acid as a biodegradable carrier for liver-specific drug delivery. Pharm Res 13:880-884.
17. Hurwitz E, Wilchek M and Pitha J (1980) Soluble macromolecules as carrier for daunorubicin. J Appl Biochem 2:25-35.
18. 1-heparin conjugate. J Pharm Sci 75:172-175.
19. Kayano K, Sakaida I, Kubota M and Okita K (1995) Functional differences between activated and normal rat liver macrophage: LPS uptake capacity by flow cytometric analysis in contrast with TNF-α release. Liver 15:253-259.
20. Mahato RI, Takemura S, Akamatsu K, Nishikawa M, Takakura Y and Hashida M (1997) Physicochemical and disposition characteristics of antisense oligonucleotide complexed with glycosylated poly(L-lysine). Biochem Pharmacol 53:887-895.
21. 2: Favorable effects on rat liver injury. Gastroenterology 102:572-576.
22. Mizushima Y and Hoshi K (1993) Recent advances in lipid microsphere technology for targeting prostaglandin delivery. J Drug Target 1:93-100.
23. 2. J Pharm Sci 62:576-580.
24. Nishikawa M, Hirabayashi H, Takakura Y and Hashida M (1995b) Design for cell-specific targeting of proteins utilizing sugar-recognition mechanism: Effect of molecular weight of proteins on targeting efficacy. Pharm Res 12:209-214.
25. Nishikawa M, Kamijo A, Fujita T, Takakura Y, Sezaki H and Hashida M (1993) Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting. Pharm Res 10:1253-1261.
26. Nishikawa M, Miyazaki C, Yamashita F, Takakura Y and Hashida M (1995a) Galactosylated proteins are recognized by the liver according to the surface density of galactose moieties. Am J Physiol 268:G849-G856.
27. Nishikawa M, Ohtsubo Y, Ohno J, Fujita T, Koyama Y, Yamashita F, Hashida M and Sezaki H (1992) Pharmacokinetics of receptor-mediated hepatic uptake of glycosylated albumin in mice. Int J Pharm. 85:75-85.
28. 1 in erectile failure: A survey of worldwide experience. J Urol 115:802-815.
29. Pratt EL (1953) Colorimetric estimation of isonicotinic acid hydrazide. Anal Chem 25:814-816.
30. Quiroga J and Prieto J (1993) Liver cytoprotection by prostaglandins. Pharmacol Ther 68:67-92.
31. 1. Prostaglandins 48:187-195.
32. Sezaki H and Hashida M (1984) Macromolecule-drug conjugates in targeted cancer chemotherapy. CRC Crit Rev Ther Drug Carrier Syst 1:1-38.
33. Sinclair SB and Levy GA (1991) Treatment of fulminant viral hepatic failure with prostaglandin E. Dig Dis Sci 36:791-800.
34. Stachura J, Tarnawski A, Ivey KJ, Mach T, Bogdal J, Szczudrawa J and Klimczyk B (1981) Prostaglandin protection of carbon tetrachloride-induced liver cell necrosis in the rat. Gastroenterology 81:211-217.
35. Takakura Y, Takagi A, Hashida M and Sezaki H (1987) Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm Res 4:293-300.
36. 2 is cytoprotective of energy metabolism and reticuloendothelial function in the ischemic canine liver. Transplant Proc XIX: 1329-1330.
37. 1 through hairless mouse skin: Combined use of carboxymethyl-ethyl-β-cyclodextrin and penetration enhancers. J Pharm Pharmacol 44:119-121.
38. Wroblewski F and La Due JS (1956) Serum glutamic pyruvic transaminase in cardiac and hepatic disease. Proc Soc Exp Biol Med 91:569-571.
39. Yamaoka K, Tanigawara Y, Tanaka H and Uno Y (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879-885.
40. 1 in dilute physiological solutions at 37 degrees C. Prostaglandins 31:923-927.